Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.20
$0.12
▼
$3.00
N/AN/A5,049 shsN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.02
+16.4%		$0.02
$0.00
▼
$0.23
N/AN/A64,867 shs72,827 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
VectivBio Holding AG stock logo
VECT
VectivBio
$16.85
$16.85
$4.25
▼
$16.98
N/AN/AN/AN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%0.00%-11.71%-24.95%-88.54%
Apollomics, Inc. stock logo
APLMW
Apollomics
+16.35%+17.09%+54.17%+12.12%-29.92%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
VectivBio Holding AG stock logo
VECT
VectivBio
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.20
$0.12
▼
$3.00
N/AN/A5,049 shsN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.02
+16.4%		$0.02
$0.00
▼
$0.23
N/AN/A64,867 shs72,827 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
VectivBio Holding AG stock logo
VECT
VectivBio
$16.85
$16.85
$4.25
▼
$16.98
N/AN/AN/AN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%0.00%-11.71%-24.95%-88.54%
Apollomics, Inc. stock logo
APLMW
Apollomics
+16.35%+17.09%+54.17%+12.12%-29.92%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
VectivBio Holding AG stock logo
VECT
VectivBio
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVOW
Alvotech
0.00
N/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00
N/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
0.00
N/AN/AN/A
VectivBio Holding AG stock logo
VECT
VectivBio
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVOW
Alvotech
$559.42MN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$8.50MN/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/AN/A
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/AN/AN/AN/A8/19/2026 (Estimated)
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/AN/AN/A9/24/2026 (Estimated)
Aravive, Inc stock logo
ARAV
Aravive
N/A-$0.90N/AN/AN/AN/AN/AN/AN/A
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest VECT, ALVOW, APLMW, and ARAV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026N/A
Alvotech stock logo
ALVOW
Alvotech
-$0.0526N/AN/AN/A$103.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
35.80%
VectivBio Holding AG stock logo
VECT
VectivBio
N/A

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
60.40%
VectivBio Holding AG stock logo
VECT
VectivBio
9.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVOW
Alvotech
4N/AN/ANot Optionable
Apollomics, Inc. stock logo
APLMW
Apollomics
59N/AN/ANot Optionable
Aravive, Inc stock logo
ARAV
Aravive
20N/AN/ANo Data
VectivBio Holding AG stock logo
VECT
VectivBio
30N/AN/ANo Data

Recent News About These Companies

Ironwood Pharma to acquire VectivBio for $1.15 bln
July 12, 2026  |  nasdaq.comhttps://www.nasdaq.com/articles/ironwood-pharma-to-acquire-vectivbio-for-$1.15-bln
VectivBio Announces Pricing of Initial Public Offering
June 16, 2026  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2021/04/08/vectivbio-announces-pricing-of-initial-public-offering
What Recent Medicare Pricing Terms Mean For The Ironwood Pharmaceuticals (IRWD) Investment Story
February 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/recent-medicare-pricing-terms-mean-070520006.html
Boston biotech settles lawsuit alleging misappropriation of GLP-2 analog intellectual property
December 23, 2025  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2025/12/23/ironwood-settles-suit-vectivbio.html
Biotech acquired by Ironwood faces allegations of misappropriating trade secrets
November 11, 2025  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2025/11/11/ironwood-vectivbio-lawsuit.html
Ironwood’s shares sink as FDA demands new trial for lead drug
April 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/ironwood-s-shares-sink-as-fda-demands-new-trial-for-lead-drug/ar-AA1CYXei
A brain biotech launches with Roche’s spare parts
February 13, 2025  |  biopharmadive.comB
Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer
January 21, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/aravax-continues-international-expansion-with-appointment-of-aled-williams-as-chief-business-officer-1034248130
CDR-Life Appoints Sarah Holland, PhD, as Chief Business Officer
December 5, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/cdr-life-appoints-sarah-holland-120000030.html
Recent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBD
November 12, 2024  |  gut.bmj.comG
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight
September 23, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/graft-versus-host-disease-market-043000895.html
Etherio Group: 2024 CMI 25
September 21, 2024  |  meetingsnet.comM
Compare with VectivBio Holding AG (VECT)
May 29, 2024  |  msn.comhttps://www.msn.com/en-nz/money/compare?id=c1dbbh
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
May 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/engene-announces-election-paul-hastings-200500599.html
Vicore Pharma Holding: Vicore Expands and Strengthens its Board of Directors
May 14, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-05/62220612-vicore-pharma-holding-vicore-expands-and-strengthens-its-board-of-directors-200.htm
Vicore Expands and Strengthens its Board of Directors
May 14, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/vicore-expands-strengthens-board-directors-062000534.html
Short Bowel Syndrome Market by 2032: Forecast Report Estimates Significant Growth
April 5, 2024  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/short-bowel-syndrome-market-2032-114900366.html
FDA approves DMD treatment from Italfarmaco
March 31, 2024  |  cen.acs.orgC
Pipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpoints
March 18, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/pipeline-moves-approval-prospects-for-sbs-candidate-rise-after-phase-iii-trial-meets-endpoints/ar-BB1k6DDg
Ironwood Nabs Phase III Win, Still Sees Stock Nosedive
March 1, 2024  |  biospace.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVOW

$0.15 0.00 (0.00%)
As of 08/5/2026

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics stock logo

Apollomics NASDAQ:APLMW

$0.02 +0.00 (+16.35%)
As of 08/6/2026 03:59 PM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

Aravive stock logo

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 08/5/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

VectivBio stock logo

VectivBio NASDAQ:VECT

$16.85 0.00 (0.00%)
As of 08/5/2026

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas